ReviewMicrobiology and molecular biology reviews : MMBR2000
Search and discovery strategies for biotechnology: the paradigm shift.
Review in Microbiology and molecular biology reviews : MMBR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed, 1 synthesis or guideline pooled it, 477 citations in OpenAlex.
- An assessment of actinobacterial diversity in the marine environment.Antonie van Leeuwenhoek · 2008Pooled it
- Review
- Global distribution of deep-sea natural products shows environmental and phylogenetic undersampling with potential for biodiscovery.Scientific reports · 2026Article
- Systematic Assessment of the Impact of Targeted Selection Methods and Environment-Mimicking Culture Conditions on Fungal Natural Product Libraries.Journal of natural products · 2026Article
- OSMAC guided bioprospecting of Atlantic sponges reveals novel bacterial species and evidence for the antimicrobial thiazole alkaloid agrochelin II.Applied and environmental microbiology · 2026Article
- Anticancer Activity of Benzomalvin Derivatives Isolated fromJournal of microbiology and biotechnology · 2025Article
- Anthozoan Chemical Defenses: Integrating Compounds, Enzymatic Activities, and Omics-Based Discoveries.International journal of molecular sciences · 2025Review
- First genome sequence and functional profiling ofFrontiers in microbiology · 2025Article
- Unlocking the biotechnological potential of Baltic microorganisms.Frontiers in microbiology · 2025Review
- Halenaquinol Blocks Staphylococcal Protein A Anchoring on Cell Wall Surface by Inhibiting Sortase A inMarine drugs · 2024Article
- The microbiota characterizing huge carbonatic moonmilk structures and its correlation with preserved organic matter.Environmental microbiome · 2024Article
- MAR4Journal of natural products · 2024Review
- Water masses influence the variation of microbial communities in the Yangtze River Estuary and its adjacent waters.Frontiers in microbiology · 2024Article
- South Africa's indigenous microbial diversity for industrial applications: A review of the current status and opportunities.Heliyon · 2023Review
- Combinatorial strategies for production improvement of anti-tuberculosis antibiotics ilamycins EBioresources and bioprocessing · 2022Article
- Discovery of unusual dimeric piperazyl cyclopeptides encoded by aProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Characterization of a Novel Shewanella algae Arginine Decarboxylase Expressed in Escherichia coli.Molecular biotechnology · 2022Article
- Deep-Sea Anemones Are Prospective Source of New Antimicrobial and Cytotoxic Compounds.Marine drugs · 2021Article
- Review
- Marine Actinomycetes, New Sources of Biotechnological Products.Marine drugs · 2021Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Profound changes are occurring in the strategies that biotechnology-based industries are deploying in the search for exploitable biology and to discover new products and develop new or improved processes. The advances that have been made in the past decade in areas such as combinatorial chemistry, combinatorial biosynthesis, metabolic pathway engineering, gene shuffling, and directed evolution of proteins have caused some companies to consider withdrawing from natural product screening. In this review we examine the paradigm shift from traditional biology to bioinformatics that is revolutionizing exploitable biology. We conclude that the reinvigorated means of detecting novel organisms, novel chemical structures, and novel biocatalytic activities will ensure that natural products will continue to be a primary resource for biotechnology. The paradigm shift has been driven by a convergence of complementary technologies, exemplified by DNA sequencing and amplification, genome sequencing and annotation, proteome analysis, and phenotypic inventorying, resulting in the establishment of huge databases that can be mined in order to generate useful knowledge such as the identity and characterization of organisms and the identity of biotechnology targets. Concurrently there have been major advances in understanding the extent of microbial diversity, how uncultured organisms might be grown, and how expression of the metabolic potential of microorganisms can be maximized. The integration of information from complementary databases presents a significant challenge. Such integration should facilitate answers to complex questions involving sequence, biochemical, physiological, taxonomic, and ecological information of the sort posed in exploitable biology. The paradigm shift which we discuss is not absolute in the sense that it will replace established microbiology; rather, it reinforces our view that innovative microbiology is essential for releasing the potential of microbial diversity for biotechnology penetration throughout industry. Various of these issues are considered with reference to deep-sea microbiology and biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.